Search - tctmd.com

Displaying 441 - 460 of 509

Sort: Relevancy | Date

News Daily News

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Jason Kahn

October 19, 2012

News Daily News

In Transradial PCI, Bivalirudin Fails to Budge Event Rates vs. Heparin

October 12, 2012

News Daily News

En la PCI Transradial, comparada con la Heparina, la Bivalirudina No Altera los Índices de Episodios

October 12, 2012

News Daily News

La Dosis de Carga Doble de Clopidogrel No Ofrece Beneficio Alguno en Pacientes con ERC que se someten a PCI Primarias

L.A. McKeown

September 18, 2012

News Daily News

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

L.A. McKeown

September 18, 2012

Presentation

Impact of Clopidogrel Loading Dose in Patients with CKD Undergoing Primary PCI for STEMI

Presenter: 56196|JY Kim

September 14, 2012

Presentation ACVS 2012

Bivalirudin Versus Heparin in STEMI

Presenter: Colonel Anil Dhall

August 03, 2012

News Daily News

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

L.A. McKeown

August 01, 2012

News Daily News

El Pantoprazol No es Necesariamente un PPI Seguro para Pacientes a Tratamiento con Terapia Antiplaquetaria Doble

L.A. McKeown

August 01, 2012

News Daily News

Stopping Clopidogrel 1 Year After MI Raises Risk in PCI Patients

Jason Kahn

July 20, 2012

News Daily News

Interrumpir el Clopidogrel 1 Año después de un IM Aumenta el Riesgo en Pacientes sometidos a PCI

Jason Kahn

July 20, 2012

News Daily News

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

July 10, 2012

News Daily News

El Ticagrelor ofrece una Inhibición Plaquetaria Más Potente que el Prasugrel

July 10, 2012

News Daily News

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

July 05, 2012

News Daily News

HORIZONS-AMI: Resultados Similares con Abciximab y Eptifibatide durante PCI Primaria

July 05, 2012

Presentation

Comparison of Abciximab vs. Eptifibatide During PCI in STEMI (from the HORIZONS-AMI Trial)

Presenter: H. S. Singh

July 05, 2012

News Daily News

Subanálisis del PLATO: El Ticagrelor es Rentable en Pacientes con SCA

June 26, 2012

News Daily News

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

June 26, 2012

News Daily News

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Caitlin E. Cox

June 07, 2012

News Daily News

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Caitlin E. Cox

June 07, 2012

Advertisement

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

In Transradial PCI, Bivalirudin Fails to Budge Event Rates vs. Heparin

En la PCI Transradial, comparada con la Heparina, la Bivalirudina No Altera los Índices de Episodios

La Dosis de Carga Doble de Clopidogrel No Ofrece Beneficio Alguno en Pacientes con ERC que se someten a PCI Primarias

Double Clopidogrel Loading Dose Offers No Benefit in Primary PCI Patients with CKD

Impact of Clopidogrel Loading Dose in Patients with CKD Undergoing Primary PCI for STEMI

Bivalirudin Versus Heparin in STEMI

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

El Pantoprazol No es Necesariamente un PPI Seguro para Pacientes a Tratamiento con Terapia Antiplaquetaria Doble

Stopping Clopidogrel 1 Year After MI Raises Risk in PCI Patients

Interrumpir el Clopidogrel 1 Año después de un IM Aumenta el Riesgo en Pacientes sometidos a PCI

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

El Ticagrelor ofrece una Inhibición Plaquetaria Más Potente que el Prasugrel

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

HORIZONS-AMI: Resultados Similares con Abciximab y Eptifibatide durante PCI Primaria

Comparison of Abciximab vs. Eptifibatide During PCI in STEMI (from the HORIZONS-AMI Trial)

Subanálisis del PLATO: El Ticagrelor es Rentable en Pacientes con SCA

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content